source
- Biotech’s new company model; The super poop behind a startup launch; and moreWelcome back to another edition of Endpoints Weekly! Earnings season is in full swing, but we had plenty of original reporting and exclusives you won’t find anywhere else this week. Chief among the…Endpoints · 3mo ago↗ source
- The OncFive: Top Oncology Articles for the Week of 5/3The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.onclive · 3mo ago↗ source
- Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 3mo ago